Logo image of ANEB

ANEBULO PHARMACEUTICALS INC (ANEB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ANEB - US0345691036 - Common Stock

2.15 USD
-0.07 (-3.15%)
Last: 12/10/2025, 8:00:00 PM
2.33 USD
+0.18 (+8.37%)
After Hours: 12/10/2025, 8:00:00 PM
Fundamental Rating

3

ANEB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. ANEB has a great financial health rating, but its profitability evaluates not so good. ANEB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ANEB had negative earnings in the past year.
ANEB had a negative operating cash flow in the past year.
In the past 5 years ANEB always reported negative net income.
In the past 5 years ANEB always reported negative operating cash flow.
ANEB Yearly Net Income VS EBIT VS OCF VS FCFANEB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -69.86%, ANEB is doing worse than 71.20% of the companies in the same industry.
ANEB has a Return On Equity (-72.78%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -69.86%
ROE -72.78%
ROIC N/A
ROA(3y)-123.91%
ROA(5y)-118.64%
ROE(3y)-132.86%
ROE(5y)-124.7%
ROIC(3y)N/A
ROIC(5y)N/A
ANEB Yearly ROA, ROE, ROICANEB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

ANEB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANEB Yearly Profit, Operating, Gross MarginsANEB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ANEB has been increased compared to 1 year ago.
The number of shares outstanding for ANEB has been increased compared to 5 years ago.
There is no outstanding debt for ANEB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANEB Yearly Shares OutstandingANEB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ANEB Yearly Total Debt VS Total AssetsANEB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

An Altman-Z score of 98.77 indicates that ANEB is not in any danger for bankruptcy at the moment.
ANEB's Altman-Z score of 98.77 is amongst the best of the industry. ANEB outperforms 97.91% of its industry peers.
There is no outstanding debt for ANEB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 98.77
ROIC/WACCN/A
WACCN/A
ANEB Yearly LT Debt VS Equity VS FCFANEB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

A Current Ratio of 24.53 indicates that ANEB has no problem at all paying its short term obligations.
ANEB has a Current ratio of 24.53. This is amongst the best in the industry. ANEB outperforms 93.19% of its industry peers.
A Quick Ratio of 24.53 indicates that ANEB has no problem at all paying its short term obligations.
The Quick ratio of ANEB (24.53) is better than 93.72% of its industry peers.
Industry RankSector Rank
Current Ratio 24.53
Quick Ratio 24.53
ANEB Yearly Current Assets VS Current LiabilitesANEB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.33% over the past year.
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 65.24% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-88.31%
EPS Next 2Y-34.34%
EPS Next 3Y-24.34%
EPS Next 5Y65.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANEB Yearly Revenue VS EstimatesANEB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2031 2032 20M 40M 60M 80M
ANEB Yearly EPS VS EstimatesANEB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANEB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANEB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANEB Price Earnings VS Forward Price EarningsANEB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANEB Per share dataANEB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

ANEB's earnings are expected to decrease with -24.34% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.34%
EPS Next 3Y-24.34%

More info and screens

0

5. Dividend

5.1 Amount

ANEB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANEBULO PHARMACEUTICALS INC

NASDAQ:ANEB (12/10/2025, 8:00:00 PM)

After market: 2.33 +0.18 (+8.37%)

2.15

-0.07 (-3.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)02-12 2026-02-12
Inst Owners54.08%
Inst Owner Change-1.75%
Ins Owners40.54%
Ins Owner Change0%
Market Cap88.32M
Revenue(TTM)N/A
Net Income(TTM)-8.48M
Analysts43.33
Price Target8.16 (279.53%)
Short Float %0.48%
Short Ratio5.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.15%
Min EPS beat(2)21.57%
Max EPS beat(2)38.73%
EPS beat(4)2
Avg EPS beat(4)-1.72%
Min EPS beat(4)-56.86%
Max EPS beat(4)38.73%
EPS beat(8)5
Avg EPS beat(8)14.23%
EPS beat(12)7
Avg EPS beat(12)10.01%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.58
P/tB 7.58
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.86%
ROE -72.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.91%
ROA(5y)-118.64%
ROE(3y)-132.86%
ROE(5y)-124.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.53
Quick Ratio 24.53
Altman-Z 98.77
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y-88.31%
EPS Next 2Y-34.34%
EPS Next 3Y-24.34%
EPS Next 5Y65.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.52%
OCF growth 3YN/A
OCF growth 5YN/A

ANEBULO PHARMACEUTICALS INC / ANEB FAQ

Can you provide the ChartMill fundamental rating for ANEBULO PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ANEB.


What is the valuation status of ANEBULO PHARMACEUTICALS INC (ANEB) stock?

ChartMill assigns a valuation rating of 0 / 10 to ANEBULO PHARMACEUTICALS INC (ANEB). This can be considered as Overvalued.


How profitable is ANEBULO PHARMACEUTICALS INC (ANEB) stock?

ANEBULO PHARMACEUTICALS INC (ANEB) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ANEB stock?

The Earnings per Share (EPS) of ANEBULO PHARMACEUTICALS INC (ANEB) is expected to decline by -88.31% in the next year.